tbuckley/cabot-search huggingface dataset:
Evaluation of disease-specific and functional symptom items on carcinoid tumor patients treated with telotristat ethyl.
Authors: Stacie Hudgens, Pablo Lapuerta, Lysbeth Floden
Journal: Journal of Clinical Oncology (2019)

427 Background: Within the pivotal, phase III TELESTAR trial, telotristat ethyl significantly reduced bowel movement (BM) frequency compared to placebo ( P &lt; 0.001) (NCT01677910). Assessing patient-related outcomes can help understand the impact of changes in BM frequency on patient lives. An analysis was done to determine whether individual items on patient-reported outcome measures show relevant patterns over the course of treatment for patients with carcinoid syndrome (CS). Methods: The TELESTAR study was a phase III, double-blind, parallel-group, randomized, placebo-controlled study comparing placebo (PBO) to telotristat ethyl (TE) in 135 patients with Carcinoid Syndrome (CS). Clinical quality of life (QoL) measurements included the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer (EORTC) GI.NET21 scales. Analyses on identified individual gastrointestinal (GI) symptom and role function items were conducted using longitudinal generalized estimation equations (GEE; reference=PBO) to characterize the likelihood of a 1-grade categorical improvement (e.g., improvement by one category on the verbal response scale). Forest plots of odds ratios (OR) and associated confidence intervals (CI) on individual items are presented. Results: At week 12, the likelihood of patients experiencing a 1-grade improvement on most GI symptoms were equivalent (OR approx. 1.0). The highest odds ratios observed with TE were for improvement in diarrhea (OR=1.86, CI=0.848-4.090) and a reduction in weight bother (OR=2.95, CI=0.713-12.199), in parallel to TELESTAR results for bowel movement frequency reduction and weight gain. Interference with daily activities (IADL) and limitations in doing work demonstrated similar outcomes (IADL OR=1.63, CI=0.617,4.288; Work OR=1.97, CI=0.722,5.376). Conclusions: The overall pattern of item level change on telotristat suggested clinical relevance for bowel movement frequency reduction and weight gain, and it was consistent with symptomatic and functional benefit in CS. Clinical trial information: NCT01677910.
Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML
Authors: Veit Bücklein, Thomas Köhnke, Frauke Schnorfeil, Klaus H. Metzeler, Nikola P Konstandin, Annika Maria Dufour, Cristina Sauerland, Wolfgang Hiddemann, Karsten Spiekermann, Marion Subklewe
Journal: Blood (2018)
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting
Authors: Francesco Costa, David Van Klaveren, Fausto Feres, Stefan James, Lorenz Räber, Thomas Pilgrim, Myeong-Ki Hong, Hyo-Soo Kim, Antonio Colombo, Philippe Gabriel Steg, Deepak L. Bhatt, Gregg W. Stone, Stephan Windecker, Ewout W. Steyerberg, Marco Valgimigli
Journal: Journal of the American College of Cardiology (2019)
Lisa M. Schwartz, MD, MS, 1963-2018
Authors: Robert Steinbrook, Rita F. Redberg
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Characterization of Gut Microbiome in Infants with Severe Respiratory Syncytial Virus Bronchiolitis
Authors: Watcharoot Kanchongkittiphon, Yanjiao Zhou, Raven Vella, Joseph Moen, Chuck Goss, Vanessa Curtis, Avraham Beigelman, Mario Castro, Leonard B. Bacharier
Journal: Journal of Allergy and Clinical Immunology (2019)
Senior NHS managers will have skills logged to stop those who fail being “moved on quietly”
Authors: Clare Dyer
Journal: BMJ (2019)

Forcing NHS whistleblowers out of their jobs is “morally abhorrent and operationally foolish,” the health and social care secretary for England told doctors as he unveiled plans for a new core list of skills for senior NHS managers.

Matt Hancock made the remarks as he told a conference in London that the government would also set up a central database to log the qualifications, experience, and employment history of NHS trust directors in England.

The two moves are part of a package recommended by a review led by Tom Kark to increase the competence of directors and to …
Sun exposure risks in athletes who were recipients of solid organ and bone marrow transplants
Authors: María V. de Gálvez, Jose M. Ruiz Sánchez, María Navarrete-de Gálvez, José Aguilera, Magdalena de Troya-Martín, Francisco Rivas-Ruiz, Enrique Herrera-Ceballos
Journal: Journal of the American Academy of Dermatology (2019)
Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development
Authors: James A King, Fox E Underwood, Nicola Panaccione, Josh Quan, Joseph W Windsor, Paulo G Kotze, Siew C Ng, Subrata Ghosh, Peter L Lakatos, Tine Jess, Remo Panaccione, Cynthia H Seow, Shomron Ben-Horin, Johan Burisch, Jean-Frédéric Colombel, Edward V Loftus, Richard Gearry, Jonas Halfvarson, Gilaad G Kaplan
Journal: The Lancet. Gastroenterology & hepatology (2019)
Sweat Chloride Testing
Authors: Cormac McCarthy, John P. Clancy, John Brewington
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 19760: Characteristics and Clinical Outcomes in Atrial Fibrillation Patients With Valvular Heart Disease: The Fushimi AF Registry
Authors: Hisashi Ogawa, Kosuke Doi, Yoshimori An, Moritake Iguchi, Masahiro Esato, Yeong-Hwa Chun, Hiromichi Wada, Koji Hasegawa, Mitsuru Abe, Masaharu Akao
Journal: Circulation (2017)

Background: Valvular atrial fibrillation (AF), defined as AF patients with prosthetic or rheumatic mitral valve, increases the risks of thromboembolism. However, outcomes of non-valvular AF patient...
Importance of Variable Selection in Multimodal Prediction Models in Patients at Clinical High Risk for Psychosis and Recent Onset Depression—Reply
Authors: Nikolaos Koutsouleris, Rachel Upthegrove, Stephen J. Wood
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study
Authors: Ulrich Mrowietz, Hervé Bachelez, A. David Burden, Michael Rissler, Christian Sieder, Roberto Orsenigo, Kamel Chaouche-Teyara
Journal: Journal of the American Academy of Dermatology (2019)

Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that is resistant to treatment. Secukinumab, an anti-interleukin 17A monoclonal antibody, is highly efficacious in the treatment of moderate-to-severe psoriasis.The primary objective was to determine the rate of achievement of a 75% improvement from baseline in Palmoplantar Psoriasis Area and Severity Index (PPPASI75) with secukinumab at week 16 versus with placebo (at a 2.5% significance level).2PRECISE was a phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing treatment with 300 mg of secukinumab (n = 79), 150 mg of secukinumab (n = 80), and placebo (n = 78) in subjects with moderate-to-severe PPP over a period of 52 weeks.The primary end point was not met. At week 16, 26.6% of subjects treated with 300 mg of secukinumab achieved PPPASI75 versus 14.1% of those who received placebo (P = .0411) (odds ratio, 2.62; 95% confidence interval, 1.04-6.60). At week 52, 41.8% of subjects treated with 300 mg of secukinumab had achieved ppPASI75. More Dermatology Life Quality Index responses of 0 or 1 were achieved with 300 mg of secukinumab (13.0%) than with placebo (4.3%) at week 16. At week 52, 43.1% of subjects receiving 300 mg of secukinumab had a Dermatology Life Quality Index response of 0 or 1. No unexpected adverse events were observed.Small sample size and characteristics of the PPP disease course.Patients with PPP who were treated with secukinumab, 300 mg, showed benefit in terms of PPPASI75 responses over 52 weeks and improved quality of life.
Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation
Authors: Jinchul Kim, Lili Yu, Wancheng Chen, Yanxia Xu, Meng Wu, Dilyana Todorova, Qingshuang Tang, Bingbing Feng, Lei Jiang, Jingjin He, Guihua Chen, Xuemei Fu, Yang Xu
Journal: Cancer Cell (2019)
Childhood Leukemia, Late Effects, and a Person-centric Model of Follow-up
Authors: Miranda M Fidler-Benaoudia, Kevin C Oeffinger
Journal: JNCI Journal of the National Cancer Institute (2019)

Survival after childhood cancer has substantially improved over the last one-half century with the introduction of chemotherapy.This is particularly true for leukemia, the most common form of childhood cancer, because it was considered incurable in the 1960s.However, with combination chemotherapy, the 5year survival rates rose to 50% in 1975-1977 and ultimately 88% in 2007-2013 in the United States (1).With time it has become clear that these lifesaving therapies may also have a long-term impact on the childhood cancer survivor, with physical and psychosocial long-term and late effects appearing not only during or soon following treatment but also decades later.Thus, there is a need to understand the longterm consequences of cancer therapy in order to risk stratify patients for upfront therapy and to monitor post therapy, following the paradigm described by Meadows to "maximize cure, minimize cost" (2).In this issue of the Journal, Sørensen and colleagues from the Adult Life after Childhood Cancer in Scandinavia study investigated such late effects of treatment by quantifying the long-term risks of hospitalization among 4003 five-year survivors of leukemia from Denmark, Sweden, Iceland, and Finland (3).Drawing on the well-developed network of hospital records in these countries and related data linkages using personal identification numbers, the authors assessed 120 diseases among survivors and determined the level of excess morbidity among survivors compared to general population control subjects.Overall, the study found that leukemia survivors have a statistically significantly greater risk of hospitalization, with 32 excess hospitalizations observed compared with that expected (per 1000 person-years).The study was also able to expand on previous work by quantifying the risks by leukemia subtype; although all subtypes exhibited statistically significantly greater multiplicative and additive excess risks, chronic myeloid leukemia (CML) survivors fared the worst with five times more hospitalizations compared with control subjects.
The Hypomorphic Gata1low Mutation Induces Fibrosis in Multiple Organs
Authors: Maria Zingariello, Laura Sancillo, Fabrizio Martelli, Paola Verachi, Claudio Bardelli, Mauro Valeri, Yujin Hoshida, Fiorella Ciaffoni, Manuela Marra, Rosa Alba Rana, Anna Rita Migliaccio
Journal: Blood (2018)
Identifying leukemia‐associated immunophenotype‐based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance
Authors: Jing‐Ni Sui, Qiu‐Sheng Chen, Yun‐Xiang Zhang, Yan Sheng, Jing Wu, Jun‐Min Li, Xiang‐Qin Weng, Bing Chen
Journal: American Journal of Hematology (2019)

Abstract Based on the leukemia‐associated immunophenotypes (LAIPs), minimal residual disease (MRD) related to the outcome can be detected by multiparameter flow cytometry in acute myeloid leukemia (AML) patients. Although 0.1% was commonly used as a cutoff value, measurable MRD or MRD level below 0.1% has also been associated with prognostic significance and more sensitive thresholds (&lt;0.1%) are required for improving AML prognosis prediction. In this study, 292 adult patients diagnosed with AML (non‐M3) were enrolled, 36 kinds of LAIPs were identified, and the baseline expression levels in normal or regenerating bone marrows of each kind of LAIP were established, which ranged from &lt;2.00 × 10 −5 to 5.71 × 10 −4 . The baseline level of each LAIP was considered as the individual threshold for MRD assessment. MRD statuses stratified by 0.1% and individual threshold were termed as 0.1%‐MRD and individual‐MRD, respectively. The patients of individual‐MRD neg showed significantly better survival compared with those of 0.1%‐MRD neg /individual‐MRD pos or 0.1%‐MRD pos . Multivariate analysis showed that when time points of complete remission, post the first and second consolidation courses, were considered, only individual‐MRD post second consolidation presented independent prognostic value. Notably, in patients of cytogenetic/molecular low‐risk (LR) or intermediate‐risk (IR), the individual‐MRD status could identify the patients with significantly different outcomes, while 0.1%‐MRD status could not. Furthermore, among the patients of the LR or IR group which received chemotherapy only, those with individual‐MRD neg status presented favorable survival, which was comparable with that of the patients accepted allogeneic hematopoietic stem cell transplantation (ASCT). This approach is useful in the selection of an ASCT strategy for clinical practice.
Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions
Authors: David M. Howard, Mark J. Adams, Toni-Kim Clarke, Jonathan D. Hafferty, Jude Gibson, Masoud Shirali, Jonathan R. I. Coleman, Saskia P. Hagenaars, Joey Ward, Eleanor M. Wigmore, Clara Alloza, Xueyi Shen, Miruna C. Barbu, Eileen Y. Xu, Heather C. Whalley, Riccardo E. Marioni, David J. Porteous, Gail Davies, Ian J. Deary, Gibran Hemani, Klaus Berger, Henning Teismann, Rajesh Rawal, Volker Arolt, Bernhard T. Baune, Udo Dannlowski, Katharina Domschke, Chao Tian, David A. Hinds, Maciej Trzaskowski, Enda M. Byrne, Stephan Ripke, Daniel J. Smith, Patrick F. Sullivan, Naomi R. Wray, Gerome Breen, Cathryn M. Lewis, Andrew M. McIntosh
Journal: Nature Neuroscience (2019)
Abstract 19380: RhoE is a Novel Factor Regulating NF-κB Signaling in Acute Myocardial Infarction
Authors: Yuan Dai, Wenjiao Li, Xiangsheng Yang, Xiaojing Yue, Tingli Yang, Xi Lin, Weijia Luo, Jiang Chang
Journal: Circulation (2017)

Introduction: A well balanced and tightly-controlled inflammation plays a crucial role in the prognosis of myocardial infarction (MI) patients. Excessive or insufficient inflammatory response can l...
Abstract 12945: A Novel Index for Quantification of Interventricular Septal Flattening in Pediatric Patients With Right Ventricular Hypertension
Authors: Konstantin Averin, Erik Michelfelder, Lindsay Urbinelli, Russel Hirsch
Journal: Circulation (2016)

Introduction: Systolic flattening of the inter-ventricular septum (IVS) is a marker of elevated right ventricular pressure (RVp). It can be non-invasively quantified by a left ventricular eccentricity index (LVEI), RV to left ventricular (LV) ratio and a novel index - the systolic flattening angle (SFA). Data evaluating the relationship between these indices and invasive RVp in pediatrics are limited. Methods: Patients referred for right and left heart cardiac catheterizations (CC) were enrolled and underwent echocardiograms after induction of anesthesia. The SFA, RV:LV ratio and LVEI were measured in end-systole. Peak systolic RVp and aortic pressure (pAo) were measured simultaneously during CC. The likelihood of SFA to predict an RVp:pAo ratio of &gt; 0.5 was assessed using receiver-operator curve (ROC) analysis. Bland-Altman plots were used to assess inter-observer agreement. Results: Forty-one unique subjects were enrolled [56% female, median age 2.7 years (0.7, 7.1) and median weight 12.1kg (6.0, 22.3)]. The median mid-ventricular (MV), apical, and sub-costal LVEI was 1.18 (0.9, 1.7), 1.18 (1.0, 1.7), and 1.13 (1.0, 1.5), respectively. The mean SFA was 8.5±9.6°, the median RV:LV ratio was 0.71 (0.46, 1.23), and the mean RVp:pAo ratio was 0.68 ± 0.5. There was a significant negative correlation (r = -0.75, p &lt;0.001) between SFA and RVp:pAo ratio and a modest correlation with other non-invasive indices (Figure). ROC analysis demonstrated an area under the curve = 0.90 for prediction of RVp:pAo &gt; 0.50 by SFA. An SFA &lt; 10.6 had a sensitivity of 88% and specificity of 79% in predicting RVp:pAo &gt; 0.50. SFA was modestly reproducible with a Bland-Altman plot demonstrating a bias of 4.14 and limits of agreement of -7.8 and 16.1. Conclusions: SFA has the best correlation with RVp:pAO, good sensitivity and specificity, but relatively high inter-observer variability. Taken together, these non-invasive measures may help minimize the need for invasive assessment of RVp.
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Matthew Smith, Chris Parker, Fred Saad, Kurt Miller, Bertrand Tombal, Quan Sing Ng, Martin Boegemann, Vsevolod Matveev, Josep Maria Piulats, Luis Eduardo Zucca, Oleg Karyakin, Go Kimura, Nobuaki Matsubara, William Carlos Nahas, Franco Nolè, Eli Rosenbaum, Axel Heidenreich, Yoshiyuki Kakehi, Amily Zhang, Heiko Krissel, Michael Teufel, Junwu Shen, Volker Wagner, Celestia Higano
Journal: The Lancet Oncology (2019)
Lansoprazole alleviates pressure overload-induced cardiac hypertrophy and heart failure in mice by blocking the activation of β-catenin
Authors: Hairuo Lin, Yang Li, Hailin Zhu, Qiancheng Wang, Zhenhuan Chen, Lin Chen, Yingqi Zhu, Cankun Zheng, Yuegang Wang, Wangjun Liao, Jianping Bin, Masafumi Kitakaze, Yulin Liao
Journal: Cardiovascular Research (2019)

Abstract Aims Proton pump inhibitors (PPIs) are widely used in patients receiving percutaneous coronary intervention to prevent gastric bleeding, but whether PPIs are beneficial for the heart is controversial. Here, we investigated the effects of lansoprazole on cardiac hypertrophy and heart failure, as well as the underlying mechanisms. Methods and results Adult male C57 mice were subjected to transverse aortic constriction (TAC) or sham surgery and then were treated with lansoprazole or vehicle for 5 weeks. In addition, cultured neonatal rat ventricular cardiomyocytes and fibroblasts were exposed to angiotensin II in the presence or absence of lansoprazole. At 5 weeks after TAC, the heart weight/body weight ratio was lower in lansoprazole-treated mice than in untreated mice, as was the lung weight/body weight ratio, while left ventricular (LV) fractional shortening and the maximum and minimum rates of change of the LV pressure were higher in lansoprazole-treated mice, along with less cardiac fibrosis. In cultured cardiomyocytes, lansoprazole inhibited angiotensin II-induced protein synthesis and hypertrophy, as well as inhibiting proliferation of fibroblasts. Lansoprazole decreased myocardial levels of phosphorylated Akt, phosphorylated glycogen synthase kinase 3β, and active β-catenin in TAC mice and in angiotensin II-stimulated cardiomyocytes. After overexpression of active β-catenin or knockdown of H+/K+-ATPase α-subunit, lansoprazole still significantly attenuated myocyte hypertrophy. Conclusion Lansoprazole inhibits cardiac remodelling by suppressing activation of the Akt/GSK3β/β-catenin pathway independent of H+/K+-ATPase inhibition, and these findings may provide a novel insight into the pharmacological effects of PPIs with regard to alleviation of cardiac remodelling.
Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis
Authors: Ghaith Abu-Zeinah, Spencer Krichevsky, Claudia Sosner, Niamh Savage, Joseph Scandura, Richard T. Silver
Journal: Blood (2018)
Abstract 10718: Efficacy and Safety of K-877, a Potent and Selective PPAR-a Agonist, in Japanese Patients With Dyslipidemia
Authors: Shun Ishibashi, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Koutaro Yokote, Tatsuhiko Kodama
Journal: Circulation (2013)

Background: Residual cardiovascular risk remains despite intensive treatment with statins. Combination therapy with fibrates may reduce such risk particularly in patients with dyslipidemia. However...